Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

ized and 219 patients were treated with balanced distribution over five groups.  The control group received macular laser therapy at baseline, and patients were eligible for repeat laser treatments, but no more frequently than at 16 week intervals.  Two groups received monthly doses of 0.5 or 2mg of VEGF Trap-Eye throughout the 12-month dosing period.  Two groups received three initial monthly doses of 2mg of VEGF Trap-Eye (at baseline and weeks 4 and 8), followed through week 52 by either every two months dosing or PRN (as-needed) dosing with very strict repeat dosing criteria. Mean gains in visual acuity versus baseline were as follows:Laser

0.5mg

monthly

2mg

monthly

2mg

every two

months*

2mg

PRN*n

44

44

44

42

45Mean change in visual acuity at week 24 versus baseline(1) (letters)

2.5

8.6**

11.4**

8.5**

10.3**Mean change in visual acuity at week 52 versus baseline (letters)

-1.3

11.0**

13.1**

9.7**

12.0***Following 3 initial monthly doses

**p<0.01 versus laser

(1) Primary endpointNo significant differences among the VEGF Trap-Eye arms were observed.  Approximately 80 percent of the VEGF Trap-Eye patients and 75 percent of the laser patients remained in the study through 52 weeks.

VEGF Trap-Eye was generally well-tolerated, and there were no ocular or non-ocular drug-related serious adverse events reported in the study.  The most common adverse events reported were those typically associated with intravitreal injections or the underlying disease. The most frequent ocular adverse events reported among patients receiving VEGF Trap-Eye included conjunctival hemorrhage, eye pain, ocular redness (hyperemia), and increased intraocular pressure.  The incidence of non-ocular serious adverse events was generally well balanced between all treatment arms. 
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... A hernia is condition in which a tissue, ... of a weak muscle area. Obesity, poor nutrition, smoking, and ... causes of hernias. There are several types of hernia such ... is when part of the abdominal tissue/organ protrudes into the ... of the umbilicus. A hiatal hernia is when a portion ...
(Date:11/26/2014)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Research and Consultancy focusing on the active pharmaceutical ingredient ... Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In ... Market – Forecast to 2020 , ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
Breaking Medicine Technology:Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... from a 52-week phase 3,study (LEADTM 3) of ... once-daily,human GLP-1 analog, were published online today in ... alone, produces statistically,significant and sustained improvements in blood ... as compared with glimepiride, a widely used,oral anti-diabetic ...
... Calif., Sept. 25 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... symptomatic intracranial hemorrhage in an earlier European,trial of ... ischemic,stroke may be minimized with avoidance of prolonged ... pressure entry criteria., The data, presented today ...
Cached Medicine Technology:Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials 2Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials 3Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials 4
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated litigation ... LLP reports. , Documents recently updated in ... records included in the state proceeding, all of ... bipolar disorder and other psychiatric conditions. Many of ...
(Date:11/27/2014)... WEDNESDAY, Nov. 26, 2014 (HealthDay News) -- Most babies ... a cold, the U.S. Food and Drug Administration says. ... be given to children younger than 2 because they ... agency warned. American adults average about three colds ... children get a cold, parents might want to give ...
(Date:11/27/2014)... (HealthDay News) -- Thanksgiving meals can pose a challenge ... an expert says. Many traditional Thanksgiving dishes -- ... -- are gluten-free, but "when it comes to pies, ... considered," Dr. Anca Safta, director of the Gluten and ... Center in North Carolina, said in a center news ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Satisfaction Can Lead to Relationship, Quality-of-Life ... ... Leading sexual wellness experts,who attended a satellite symposium of the American ... agreed that,better intimacy can lead to better relationships and ultimately, better,overall ...
... threat, study finds, , , WEDNESDAY, Nov. 12 (HealthDay News) -- Whether ... you have a higher risk of dying than someone of normal ... to collect their weight around the middle -- apple-shaped -- face ... tends to settle in their hips and thighs -- pear-shaped. ...
... Medical Simulation Corporation (MSC),announces a new partnership with the ... and education services for USF Health hospital partners and ... education. The MSC SimSuite Education Center is located at ... , "MSC is excited to partner with USF Health ...
... cost-containment. , ... Alexandria, VA (Vocus) November 12, 2008 ... Chain Drug Stores (NACDS) Steven C. Anderson, IOM, CAE issued a ... Finance Committee Chairman Max Baucus (D-MT) today:, , , , ,“It ...
... that Hydrates and Soothes Young Throats Now Available,Across ... As cough and cold season,rapidly approaches, Integrated ... and nutrition products has launched its newest product,in ... product is a perfect choice for parents who ...
... industry award for 2008, WASHINGTON, Nov. ... of furniture for healthcare environments, today announced ... Nightingale Award at the,annual Healthcare Design 08 ... workspace solution, SYNC(TM)., (Photo: http://www.newscom.com/cgi-bin/prnh/20081112/AQW138 ...
Cached Medicine News:Health News:Experts at American Society for Reproductive Medicine (ASRM) Satellite Symposium Reach Consensus: Better Intimacy = Better Overall Well-Being 2Health News:Experts at American Society for Reproductive Medicine (ASRM) Satellite Symposium Reach Consensus: Better Intimacy = Better Overall Well-Being 3Health News:Excess Weight Ups Risk of Death, No Matter Where It Collects 2Health News:Medical Simulation Corp. announces partnership with University of South Florida 2Health News:As Chairman Baucus Outlines Vision for Healthcare Reform, NACDS Emphasizes Pharmacy's Essential Role in Any Successful Overhaul 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution 2Health News:Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution 3
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 left angled suture passer....
45 right angled suture passer....
Medicine Products: